Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer

Authors: K. Miller, Judd W. Moul, Martin Gleave, Karim Fizazi, James B. Nelson, Thomas Morris, Faith E. Nathan, Stuart McIntosh, Kristine Pemberton, Celestia S. Higano - Prostate Cancer and Prostatic Diseases 2013 cited by 91